FDA Announces Fee Rate for Rare Pediatric Disease Priority Review Voucher for Fiscal Year 2017

Summary

The US Food and Drug Administration (FDA) has set the fee for using a rare pediatric disease priority review voucher for fiscal year 2017, based on the average cost of reviewing human drug applications subject to priority review versus those not subject to priority review in the previous fiscal year.